logo
Twitter
Discord
Email
logo
Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals, Inc.

NASDAQ•ELDN
CEO: Dr. David-Alexandre C. Gros M.D., Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2014-09-17
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for kidney transplantation, xenotransplantation, and liver transplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Contact Information
19900 MacArthur Boulevard, Suite 550, Irvine, CA, 92612, United States
949-238-8090
eledon.com
Market Cap
$128.29M
P/E (TTM)
-2.1
37
Dividend Yield
--
52W High
$4.97
52W Low
$1.35
52W Range
22%
Rank48Top 64.4%
3.3
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 3.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$0.00+0.00%
4-Quarter Trend

EPS

-$0.23-121.55%
4-Quarter Trend

FCF

-$14.48M+23.01%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

R&D Spending Increased Research and development expenses rose $14.74M to $48.78M for nine months ended September 30, 2025, supporting clinical trials.
Warrant Liability Decreased Fair value of warrant liabilities fell $22.92M to $21.95M, reflecting stock price decline and recognized as income.
Recent Financing Secured Successfully closed November 2025 offering, raising approximately $53.6M in net proceeds to fund future operations and development.
Net Loss Widened Nine months net loss reached $35.17M, reversing prior period's $8.43M net income due to operational costs.

Risk Factors

Continued Operating Losses Expect recurring net losses for several years; requires substantial additional capital to fund ongoing research and development activities.
Clinical Development Uncertainty Product candidates are in early stages; failure to successfully develop or gain approval will materially harm business prospects.
Significant Stock Dilution Need for future capital raises via equity or debt risks significant dilution to existing common stockholders' ownership interests.
Material Weakness Persists Disclosure controls and procedures were not effective due to an unresolved material weakness in internal control over financial reporting.

Outlook

Kidney Program Prioritization Strategy focuses on advancing tegoprubart for kidney transplant rejection; ALS development requires specific additional financing to continue.
Cash Runway Projection Current cash resources are estimated sufficient to meet anticipated cash needs for at least the next 12 months.
Seek Additional Capital Anticipates needing additional financing beyond 12 months via equity, debt, or strategic collaborations to fund future operations.
Advance Regulatory Filings Plans to continue clinical development, manufacturing scale-up, and seek marketing approval for product candidates in key indications.

Peer Comparison

Revenue (TTM)

Innate Pharma S.A.IPHA
$36.93M
-61.2%
Tonix Pharmaceuticals Holding Corp.TNXP
$10.30M
-145.5%
Nkarta, Inc.NKTX
$9.03M
-14.3%

Gross Margin (Latest Quarter)

Applied Therapeutics, Inc.APLT
100.0%
+0.0pp
Fate Therapeutics, Inc.FATE
100.0%
+0.0pp
Tonix Pharmaceuticals Holding Corp.TNXP
58.5%
+13.6pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
ACHV$298.11M-3.7-196.7%19.1%
TNXP$234.28M-1.6-55.2%0.2%
AVTX$177.88M-2.2-88.4%0.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 19, 2026
|
EPS:-$0.20
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 14, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.23-121.6%
    N/A

  • Form 10-K/A - FY 2024

    Period End: Dec 31, 2024|Filed: Aug 14, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.75-46775.0%
    N/A

  • Form 10-Q/A - Q1 2025

    Period End: Mar 31, 2025|Filed: Aug 14, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.08-89.3%
    N/A

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 14, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.15-85.8%
    N/A

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 14, 2025|Refer to amended data

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 20, 2025|Refer to amended data

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 12, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $1.05-400.0%
    N/A

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 19, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-1.06+165.0%
    N/A